[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601835":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":19,"id":46,"slug":19,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":19,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":19,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BsAbs-treatment group","EXPERIMENTAL","Patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration will receive radiation combined with a BCMA\u002FCD3 bispecific antibody (CM336)",[13],"Drug: BCMA\u002FCD3 bispecific antibody (CM336)",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","BCMA\u002FCD3 bispecific antibody (CM336)",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Gang An, MD","CONTACT","13502181109","angang@ihcams.ac.cn",[27],{"facility":28,"status":29,"city":30,"state":19,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences","RECRUITING","Tianjin","300020","China","CN",{"type":35,"coordinates":36},"Point",[37,38],117.17667,39.14222,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":19,"email":25},"Gang An, PhD&MD","008613502181109",{"type":45,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100601835",false,"NCT07115667","Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","A Prospective Single-Arm Clinical Trial of Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","Inclusion Criteria:\n\n* ≥18 years old\n* Histologically confirmed SBP with \\\u003C10% clonal plasma cells in marrow\n* ECOG ≤ 2\n* No prior anti-myeloma therapy. Previous local radiotherapy for SBP is not an exclusion criterion.\n* Meets laboratory and imaging criteria\n\nExclusion Criteria:\n\n1. Patients who have previously received anti-plasma cell therapy, including melphalan, cyclophosphamide, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, or chimeric antigen receptor T-cell (CAR-T) therapy.\n2. Any condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.","ALL","18 Years","78 Years",{"count":56,"type":57},21,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA\u002FCD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.",[63,64,65],"Solitary Bone Plasmacytoma","Plasmacytoma of Bone","Plasma Cell Disorders",[67,68],"solitary bone plasmacytoma","BCMA\u002FCD3 bispecific antibody","2025-09-05",{"date":71,"type":72},"2025-09-08","ACTUAL",{"date":74,"type":72},"2025-08-25",{"date":76,"type":57},"2027-12-01",{"name":5,"class":6},1]